The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo

Cancer Research

Volumn 65, Issue 13, 2005, Pages 5620-5627

  Osthus, Rebecca C ^a   Karim, Baktiar ^a   Prescott, Julia E ^a   Smith, B Douglas ^b   McDevitt, Michael ^a,b   Huso, David L ^a   Dang, Chi V ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR;

ANIMAL CELL; ARTICLE; BLAST CELL CRISIS; CANCER; CDCA7 GENE; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; GENE; GENE OVEREXPRESSION; GENE TARGETING; GENETIC REGULATION; GENETIC RISK; JPO1 GENE; LYMPHATIC SYSTEM TUMOR; LYMPHOID TISSUE; MOUSE; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROMOTER REGION; SOLID TUMOR; TRANSGENE; TUMOR GROWTH;

ALLELES; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENES, MYC; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 21344455515     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0536     Document Type: Article

References (27)

1. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 2001;20:5595-610.
2. Shen-Ong GL, Keath EJ, Piccoli SP, Cole MD. Novel myc oncogene RNA from abortive immunoglobulin-gene recombination in mouse plasmacytomas. Cell 1982;31:443-52.
3. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc one gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982;79:7824-7.
4. Dalla-Favera R, Martinotti S, Gallo RC, Erikson J, Croce CM. Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science 1983;219:963-7.
5. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999;18:3004-16.
6. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999;19:1-11.
7. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 2003;4:R69.
8. Levens DL. Reconstructing MYC. Genes Dev 2003;17:1071-7.
9. Levens D. Disentangling the MYC web. Proc Natl Acad Sci U S A 2002;99:5757-9.
10. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000;16:653-99.
11. Cole MD, McMahon SB. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 1999;18:2916-24.
12. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: marvelously complex. Adv Cancer Res 2002;84:81-154.
13. Lewis BC, Shim H, Li Q, et al. Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene. Mol Cell Biol 1997;17:4967-78.
14. Whitfield ML, Sherlock G, Saldanha AJ, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002;13:1977-2000.
15. Prescott JE, Osthus RC, Lee LA, et al. A novel c-Myc-responsive gene, JPO1, participates in neoplastic transformation. J Biol Chem 2001;276:48276-84.
16. Haggerty TJ, Zeller KI, Osthus RC, Wonsey DR, Dang CV. A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. Proc Natl Acad Sci U S A 2003;100:5313-8.
17. Dildrop R, Ma A, Zimmerman K, et al. IgH enhancer-mediated deregulation of N-myc gene expression in transgenic mice: generation of lymphoid neoplasias that lack c-myc expression. EMBO J 1989;8:1121-8.
18. Malek SN, Dordai DI, Reim J, Dintzis H, Desiderio S. Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase. Proc Natl Acad Sci U S A 1998;95:7351-6.
19. Huang A, Ho CSW, Ponzielli R, et al. Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells. Cancer Res 2005;65:5607-19.
20. Dolde CE, Mukherjee M, Cho C, Resar LM. HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat 2002;71:181-91.
21. Handa H, Hegde UP, Kotelnikov VM, et al. The effects of 13-cis retinoic acid and interferon-α in chronic myelogenous leukemia cells in vivo in patients. Leuk Res 1997;21:1087-96.
22. Jennings BA, Mills KI. c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia. Leuk Res 1998;22:899-903.
23. Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 2002;21:7137-46.
24. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992;70:901-10.
25. Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T. Chronic myelogenous leukemia molecular signature. Oncogene 2003;22:3952-63.
26. Adams JM, Cory S. Transgenic models of tumor development. Science 1991;254:1161-7.
27. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533-8.